Podcasts about Leukemia

Os avanços da ciência transformaram o tratamento dos cânceres hematológicos,ampliando as possibilidades terapêuticas e contribuindo para o aumento da sobrevida depacientes com doenças como o mieloma múltiplo. Ainda assim, diagnóstico, recaídas,acesso ao tratamento e qualidade de vida permanecem entre os desafios da jornada.¹ ⁴Neste episódio do podcast Notícia no Seu Tempo, a jornalista Carla Fiorio conversacom os hematologistas Walter Moisés Tobias Braga, médico responsável peloAmbulatório de Mieloma Múltiplo da Universidade Federal de São Paulo (SP 114081);e Deise Almeida (SP 149683), médica e diretora médica de Oncologia e Hematologia daGSK Brasil, sobre mieloma múltiplo e mielofibrose, duas doenças que fazem parte douniverso da onco-hematologia. A conversa aborda os avanços da medicina, asnecessidades que ainda não foram atendidas e as perspectivas para o futuro do cuidado. Este episódio é uma produção do Estadão Blue Studio com patrocínio da GSK.Referências para o texto de apresentação: 1. Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed andrefractory multiple myeloma. Blood. 2015;125(20).2. Hungria V, et al. Emerging Real-World Treatment Patterns and ClinicalOutcomes of Multiple Myeloma in Argentina and Brazil: Insights from theTOTEMM Study in the Private Healthcare Sector. Curr Oncol. 2026;33:16.3. Eisfeld C, et al. Time trends in survival and causes of death in multiple myeloma.BMC Cancer. 2023.4. IQVIA Institute. Global Oncology Trends 2025.Referências para o episódio: 1. Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed andrefractory multiple myeloma. Blood. 2015;125(20). REF-480872. CA: A Cancer Journal for Clinicians. Vol. 70. 2020. p. 7–30. REF-724913. Kazandjian D. Multiple myeloma epidemiology and survival: A uniquemalignancy. Semin Oncol. 2016;43(6):676–81. REF-2960414. Hungria, V.; Maiolino, A.; Pessoa de Magalhães, R.J., Filho; Pitombeira deLacerda, M.; Remaggi, G.; Scibona, P.; Seehaus, C.; Brulc, E.; Savoy, N.; Fantl,D.; et al. Emerging Real-World Treatment Patterns and Clinical Outcomes ofMultiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Studyin the Private Healthcare Sector. Curr. Oncol. 2026, 33, 16.https://doi.org/10.3390/curroncol33010016. REF-316596 5. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5thedition of the World Health Organization Classification of HaematolymphoidTumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia.2022;36:1703–1719. doi:10.1038/s41375-022-01613-1 REF-2279396. Eisfeld C. et al. Time trends in survival and causes of death in multiplemyeloma. BMC Cancer. 2023. REF-3161117. IQVIA Institute. Global Oncology Trends 2025. REF-3191028. Observatório de Oncologia. Panorama do Mieloma Múltiplo no SUS [acesso emjul2026]. https://observatoriodeoncologia.com.br/estudos/cancer-de-sangue/mieloma-multiplo/2024/panorama-do-mieloma-multiplo/ REF-2963359. International Myeloma Foundation Latin America. Mieloma múltiplo: segundotipo de câncer sanguíneo mais frequente no mundo [Internet]. São Paulo: IMFLA; 2022 jun 07 [acesso em jul2026]. https://myeloma.org.br/mieloma-multiplo-segundo-tipo-de-cancer-sanguineo-mais-frequente-no-mundo/. REF-26981910. Kumar SK et al. Multiple Myeloma. Nature Reviews Disease Primers. 2017.REF-1817111. Yu B et al. BCMA-targeted immunotherapy for multiple myeloma. Journal ofHematology & Oncology. 2020. REF-10177912. Wang R et al. Antibody–Drug Conjugates (ADCs): current and futurebiopharmaceuticals. Journal of Hematology & Oncology. 2025. REF-28457113. Scherber RM, Mesa RA. Management of challenging myelofibrosis after JAKinhibitor failure. Blood Reviews. 2020. REF-16832614. Nicolosi M et al. Sex and degree of severity influence the prognostic impact ofanemia in primary myelofibrosis. Leukemia. 2018. REF-30724015. Mughal TI et al. Myelofibrosis-associated complications. International Journalof General Medicine. 2014. REF-16520816. Naymagon L, Mascarenhas J. Myelofibrosis-Related Anemia: Current andEmerging Therapeutic Strategies. Hemasphere. 2017. REF-16521017. OJJAARA® (momelotinibe). Bula do produto; Consulta Pública ANS sobreincorporação para mielofibrose. REF-32111518. Hungria, V; et al. Belantamab mafodotin plus bortezomib and dexamethasone inpatients with relapsed or refractory multiple myeloma (DREAMM-7): updatedoverall survival analysis from a global, randomised, open-label, phase 3 trial.Lancet Oncol 2025 Published Online July 15, 2025 https://doi.org/10.1016/S1470-2045(25)00330-4. REF-24715319. Mukhopadhyay, P., Abdullah, H.A., Opalinska, J.B. et al. The clinical journey ofbelantamab mafodotin in relapsed or refractory multiple myeloma: lessons indrug development. Blood Cancer J. 15, 15 (2025).https://doi.org/10.1038/s41408-025-01212-0. REF-24715320. ABBAS, A. K.; LICHTMAN, A. H.; PILLAI, S. Cellular and molecularimmunology. 10. ed. Philadelphia: Elsevier, 2022. REF-30571621. BIRGEGARD, G. et al. Inflammatory functional iron deficiency common inmyelofibrosis, contributes to anaemia and impairs quality of life. EuropeanJournal of Haematology, 2019; 102:235–240. REF-32205922. Al Noumani I; Expert Opinion on Pharmacotherapy; 2026; 27(8), 657–668.REF-331446 Material dirigido ao público geral. Por favor, consulte o seu médico. NP-BR-MMU-WCNT-260004/SETEMBRO DE 2026See omnystudio.com/listener for privacy information.

In today's episode, we spoke with Elias Jabbour, MD, and Dennis Kim, MD. Dr Jabbour is a professor of Leukemia at The University of Texas MD Anderson Cancer Center in Houston. Dr Kim is an associate professor at the Institute of Medical Science at the University of Toronto in Canada.In our exclusive interview, Drs Jabbour and Kim discussed the third-generation TKI olverembatinib (HQP1351), how it works, and its advantages compared with other treatment options for chronic myeloid leukemia and acute lymphoblastic leukemia. Additionally, the 2 experts overviewed data for the investigational TKI that came out of the 2026 ASCO Annual Meeting like the phase 1b HQP1351CU101 trial (NCT04260022) and a single-arm, multicenter study (ChiCTR2200061655), as well as the next steps for olverembatinib like in the ongoing phase 3 POLARIS-2 (NCT06423911) trial.

What happens when your life changes overnight with a diagnosis that seems impossible to overcome?On this episode of This Week in America with Ric Bratton, author Janet McDowell shares the remarkable true story behind her memoir, Chasing a Light in the Darkness: A Story of Resilience in the Face of Unrelenting Medical Challenges.Shortly after her 61st birthday, Janet was diagnosed with lymphocytic leukemia. What followed was a years-long battle that included two near-death experiences, a stem cell transplant, serious rejection complications, and countless setbacks. Yet through every obstacle, Janet refused to surrender hope. BookBabyIn this deeply personal conversation, Janet discusses receiving a life-changing leukemia diagnosis, enduring life-threatening medical complications, the emotional challenge of asking for help, the vital role her sister Susan played as caregiver, finding hope during overwhelming uncertainty, and the lessons she learned about resilience, courage, gratitude, and perseverance.Whether you've faced illness yourself, cared for a loved one, or simply need encouragement during difficult times, Janet's story is a powerful reminder that hope can shine even in life's darkest moments.This Week in America with Ric Bratton brings listeners compelling conversations with authors, thought leaders, medical experts, business innovators, and extraordinary individuals whose stories educate, inspire, and entertain.If you're searching for inspiration through cancer recovery, leukemia survivor stories, medical memoirs, stem cell transplant experiences, caregiver support, resilience, hope, and overcoming life's greatest challenges, don't miss this moving conversation with Janet McDowell.KeywordsJanet McDowell, Chasing a Light in the Darkness, leukemia survivor, lymphocytic leukemia, cancer survivor, cancer recovery, stem cell transplant, graft versus host disease, medical memoir, inspirational memoir, resilience, hope, perseverance, caregiver support, family caregiving, overcoming adversity, chronic illness, healing journey, cancer treatment, patient story, health podcast, inspirational author, memoir interview, medical challenges, surviving cancer, This Week in America, Ric Bratton, podcast interview, overcoming illness, hope after cancer

What happens when your life changes overnight with a diagnosis that seems impossible to overcome?On this episode of This Week in America with Ric Bratton, author Janet McDowell shares the remarkable true story behind her memoir, Chasing a Light in the Darkness: A Story of Resilience in the Face of Unrelenting Medical Challenges.Shortly after her 61st birthday, Janet was diagnosed with lymphocytic leukemia. What followed was a years-long battle that included two near-death experiences, a stem cell transplant, serious rejection complications, and countless setbacks. Yet through every obstacle, Janet refused to surrender hope. BookBabyIn this deeply personal conversation, Janet discusses receiving a life-changing leukemia diagnosis, enduring life-threatening medical complications, the emotional challenge of asking for help, the vital role her sister Susan played as caregiver, finding hope during overwhelming uncertainty, and the lessons she learned about resilience, courage, gratitude, and perseverance.Whether you've faced illness yourself, cared for a loved one, or simply need encouragement during difficult times, Janet's story is a powerful reminder that hope can shine even in life's darkest moments.This Week in America with Ric Bratton brings listeners compelling conversations with authors, thought leaders, medical experts, business innovators, and extraordinary individuals whose stories educate, inspire, and entertain.If you're searching for inspiration through cancer recovery, leukemia survivor stories, medical memoirs, stem cell transplant experiences, caregiver support, resilience, hope, and overcoming life's greatest challenges, don't miss this moving conversation with Janet McDowell.KeywordsJanet McDowell, Chasing a Light in the Darkness, leukemia survivor, lymphocytic leukemia, cancer survivor, cancer recovery, stem cell transplant, graft versus host disease, medical memoir, inspirational memoir, resilience, hope, perseverance, caregiver support, family caregiving, overcoming adversity, chronic illness, healing journey, cancer treatment, patient story, health podcast, inspirational author, memoir interview, medical challenges, surviving cancer, This Week in America, Ric Bratton, podcast interview, overcoming illness, hope after cancer

INTRODUCTION:Fever of Unknown Origin, or FUO: We have all had a fever at some point—maybe from seasonal flu or a brief stomach bug—where the body turns up the heat, fights off the bug, and recovers in a couple of days. Fever is a very efficient defense mechanism to fight microorganisms by making your body a hostile environment where they cannot survive. But what happens when a fever lasts for weeks, standard tests come back normal, and usual fever reducing medications do not seem to work?We will talk about the surprising root causes, the latest imaging technology like PET scans, and what to do when a fever refuses to break. Whether you are a medical student, a healthcare professional, or simply curious about how our body's defense mechanisms work, this episode is for you. Let us get into it!Definition of Fever of Unknown Origin.A standard fever is like a smoke alarm going off when you burn toast—you quickly spot the cause, fix it, and the alarm stops. FUO is like an alarm ringing continuously for weeks, but despite searching every room, you cannot find the source of the fire.Clinical Criteria (Classic FUO):1. Temperature >38.3 C measured on multiple occasions.2. Duration of at least 3 weeks.3.Unexplained after 1 week of intensive outpatient or inpatient evaluation (or three outpatient visits).Categories of FUO.1. Classic FUO: The traditional presentation described above.2. Nosocomial (Hospital-Acquired) FUO: Fevers in hospitalized patients without infection upon admission.3. Neutropenic FUO: Fevers in immunocompromised patients (e.g., undergoing chemotherapy) with low white blood cell counts.4. HIV-Associated FUO: Fevers lasting weeks in patients with HIV, often driven by opportunistic infections like Tuberculosis or CMV, that stands for cytomegalovirus. What a mouthful!The Big Four Causes are:Infections (~30–40%): Atypical presentations of common diseases (e.g., hidden abscesses, endocarditis, tuberculosis, or tick-borne illnesses). Our priority will be to determine if this patient is having an infection, unless we get clinical manifestations that would guide us in another direction.Autoimmune & Inflammatory Diseases (~20–30%): The immune system overreacting and attacking the body's tissues (e.g., Adult-onset Still's disease, Temporal Arteritis/Giant Cell Arteritis, Lupus).Malignancies / Cancers (~10–20%): Blood cancers (Lymphoma, Leukemia) or solid tumors (Renal cell carcinoma). Infections, autoimmune/inflammatory diseases, and malignancies cover 60-90% of the causes of FUO.Miscellaneous / Drug Fevers (~10–15%): "Drug fever" caused by adverse reactions to common medications (e.g., antibiotics, anti-seizure meds), thyroid storm, or deep vein thrombosis (DVT).Modern Medicine: Advanced imaging (CT, MRI, PET scans) which have helped us diagnose cancers and abscesses much earlier. As a result, modern FUOs are increasingly driven by autoimmune conditions, non-infectious inflammatory disorders. Sometimes it feels like we solve one problem and uncover another one!Important: Some cases remain undiagnosed (up to 30–50%) and resolve without a specific label.Diagnostic Approach:Step 1: The "Detective Work" (History & Physical):● Detailed History: Travel history, animal exposure (ticks, pets), occupational hazards, social history, medication review (to exclude drug fevers), and family history.● Potential Diagnostic Clues: Looking for subtle signals (e.g., a new heart murmur, temporal tenderness, hidden skin rashes, or swollen lymph nodes).Step 2: Basic Tiered Testing:● Blood Work: CBC (complete blood count), inflammatory markers (ESR, CRP, Ferritin), comprehensive metabolic panel, blood cultures.● Targeted Serologies: HIV, viral panels, autoimmune antibodies (ANA, Rheumatoid Factor).● Initial Imaging: Chest X-ray, abdominal ultrasound.Step 3: Advanced Diagnostic Workup:FDG-PET/CT Imaging: One of the most significant updates in recent guidelines. FDG-PET/CT uses a radioactive sugar tracer to highlight areas of high metabolic activity (inflammation, infection, tumor) throughout the entire body in a single scan. FDG-PET is a functional nuclear-imaging technique that uses ¹⁸F-fluoro-deoxy-glucose (FDG) — a radioactive glucose analog — to map tissue glucose metabolism.Targeted Biopsies: Biopsying tissues guided by PET scan findings (e.g., lymph node, liver, or temporal artery)."Refractory" Fevers:Fever vs. Hyperthermia: Standard fevers are driven by the brain's hypothalamus resetting the body's thermostat upward (often mediated by prostaglandins). ● Antipyretics (acetaminophen, NSAIDs) block prostaglandin synthesis.● If a fever does not respond to antipyretics, it may indicate non-prostaglandin-mediated inflammation (e.g., severe cytokine storm, drug-induced hyperthermia, or central nervous system dysregulation).Empiric Treatment vs. Observation:● The "Hold Your Horses" Principle: Current guidelines strongly advise against starting empirical antibiotics or steroids right away in stable patients. Antibiotics can mask infections and produce false-negative culture results, while steroids can hide inflammatory signs or exacerbate hidden infections.● When to Treat Empirically: Reserved for hemodynamically unstable patients, neutropenic patients, or specific high-suspicion conditions (e.g., suspected Temporal Arteritis to prevent blindness).Diagnostic Trial: Naproxen Test (Historical & Clinical Pearl): A brief trial of naproxen can sometimes distinguish tumor fevers (which often drop sharply in response to NSAIDs) from infectious fevers, though it is used cautiously as a supportive diagnostic clue rather than a rule. So, if a patient responds to a trial of naproxen, then we can suspect a tumor as a cause of the patient's fevers. But it is not a strong recommendation.A 2019 systematic review/meta-analysis (15 studies, 582 patients) found a 94.1% success rate for naproxen in treating confirmed neoplastic fever. The test is not specific and lacks validation, but I can see the importance of knowing this: Naproxen is effective against cancer fever.FUO evaluation is a marathon, not a sprint. Re-evaluating the patient daily in the hospital for new physical clues is often more valuable than ordering endless specialized tests. I would like to emphasize that modern tools PET/CT have transformed how quickly we locate hidden inflammation. Also, let us remember that a huge proportion of undiagnosed FUOs eventually resolve spontaneously with good long-term outcomes, provided serious conditions have been systematically ruled out.Take away messages:First, FUO is a diagnostic marathon, not a sprint. Finding the cause takes patient detective work, careful daily exams, and targeted testing rather than rushing into quick fixes.Second, modern imaging like FDG-PET scans has completely transformed how we spot hidden inflammation and infection long before standard blood work gives us an answer.And finally, 'refractory' fevers require caution. If a fever is not responding to standard antipyretics, starting antibiotics or steroids right away can hide the real culprit. In stable patients, holding off and continuing the search is often the safest path.__________________Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!References:1) David AB, Quinlan JD. Fever of Unknown Origin in Adults. American Family Physician. 2022;105(2):137-143.2) Wright WF, Stelmash L, Betrains A, Mulders-Manders CM, Rovers CP, Vanderschueren S, Auwaerter PG; International Fever and Inflammation of Unknown Origin Research Working Group. Recommendations for Updating Fever and Inflammation of Unknown Origin From a Modified Delphi Consensus Panel. Open Forum Infectious Diseases. 2024;11(7):ofae298.3) Wright WF, Durso SC, Forry C, Rovers CP. Fever of unknown origin. BMJ. 2025;388:e080847.4) Wright WF, Auwaerter PG. Fever and fever of unknown origin: review, recent advances, and lingering dogma. Open Forum Infectious Diseases. 2020;7(5):ofaa132.5) Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach. The American Journal of Medicine. 2015;128(10):1138.e1-1138.e15.6) Nazar AH, Naswa N, Sharma P, et al. Spectrum of 18F-FDG PET/CT findings in patients presenting with fever of unknown origin. American Journal of Roentgenology. 2012;199(1):175-1851) Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College in Tianjin, China, on his latest article published in Blood titled "Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia." In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received a course of venetoclax combined with pediatric-inspired chemotherapy, to determine the results of this treatment on MRD negativity.

In this episode, Michael Dargie sits down with Noelle Labrie, a learning and development professional who helps restaurant owners and their teams lead better. Calling in from Miramar Beach on the Emerald Coast of Florida, Noelle explains that she doesn't walk into a kitchen and tell anyone they're bad at leadership. Instead she looks at turnover, staff culture, and online reviews, then works with management and chefs to figure out how they can serve their staff so their staff can serve their guests. Her favourite people to work with are the newly promoted, young not in years but in experience. The awesome line cook or standout server who suddenly gets a supervisory role and has no idea how to hold yesterday's drinking buddies accountable, read a P&L, or control food and labour costs. Nobody teaches them, and that gap is exactly where Noelle likes to work. Her eight-week Carpe Diem Leadership program breaks that learning into small, digestible tasks with an in-theory, in-practice, in-review rhythm each week. Then there's the streak. As of the recording, Noelle had run at least a mile every single day for 3,792 days, roughly ten and a half years. It started almost by accident. A marathon fundraiser for the Leukemia and Lymphoma Society took her to Dublin for her 30th birthday, where she promptly fell in love with Ireland. Years later, wrapping up a work contract in Costa Rica, she decided to run a mile a day until her flight home. Forty days became a hundred, and she simply never stopped. What began as physical health has become far more about her emotional, spiritual, and mental wellbeing, the way she clears her head and sets her intention each morning. The conversation wanders happily, the way the best ones do. Noelle has run six marathons, most recently New York City for her 50th birthday. She's run in a Tahiti airport in flip-flops while crossing the date line, and she's lived and worked in Kuwait for four years, opening a restaurant in Istanbul, a city she'd move to tomorrow if she spoke the language. A quiet moment outside her Kuwait apartment, two single women dressed head to toe in black, one in a hijab, left her with a lasting thought: are we really that different? That thread carries into her answer for the one thing she wishes the world knew, that we are far more alike than we are different, and that a little more compassion and empathy would go a long way. Her advice for rebels is just as human. Be gentle with yourself. Show yourself grace. Know that your best will look different every day, sometimes 100 percent and sometimes 14, and that both are fine. You can find Noelle on LinkedIn and at Tri-Skill Consulting. Episode Highlights [00:34,000] The Emerald Coast | Noelle calls in from Miramar Beach, Florida, where she followed her retired parents to white sugar sand and crystal-clear water. [01:36,000] What she actually does | A learning and development pro who helps restaurant leaders with turnover, staff culture, and reviews, not by telling them they're bad at leadership. [02:30,000] Serve the staff first | Her whole approach: help management and chefs serve their staff so the staff can serve their guests. [03:52,000] Her favourite people | The newly promoted, young in experience, who were great servers or cooks and now have to lead without anyone teaching them how. [06:19,000] 3,792 days and counting | Noelle reveals her run streak: at least a mile every single day for over ten years. [07:16,000] How it started | A marathon fundraiser for the Leukemia and Lymphoma Society, and an $8,000 goal, pulled a non-runner into the sport. [08:12,000] Dublin and coming home | She ran her first marathon in Dublin for her 30th birthday and felt she'd come home the moment she stepped off the plane. [09:41,000] Costa Rica turns 40 into 100 | A mile a day to close out a work contract became 40 days, then 100, then a habit she never broke. [11:01,000] More than physical | Over the years the streak became about emotional, spiritual, and mental health, a daily reset and intention setting. [11:38,000] Six marathons | From Dublin at 30 to New York City in 2023 for her 50th birthday. [14:09,000] Carpe Diem Leadership | Her eight-week program turns everyday moments into small, manageable leadership lessons for busy restaurant teams. [17:43,000] Running in Tahiti | Crossing the date line with a short layover, she ran between the seats of an open-air airport in flip-flops to keep the streak alive. [20:43,000] Falling for Istanbul | Living in Kuwait and opening a restaurant in Istanbul, she fell so hard for the city she'd have stayed if she spoke the language. [23:21,000] Two women in black | A quiet morning outside her Kuwait apartment left her asking whether we're really that different from one another. [25:02,000] The one thing she wishes | That we're more alike than different, and that a little more compassion and empathy would help. [30:33,000] Advice for rebels | Be gentle with yourself, show yourself grace, and remember your best looks different every day, sometimes 100 percent, sometimes 14. Links From This Episode Tri-Skill Consulting Noelle Labrie on LinkedIn Leukemia and Lymphoma Society TCS New York City Marathon Dublin Marathon Full show notes, transcript, and more: https://rebelrebelpodcast.com/episodes/streaking-into-self-discovery-with-noelle-labrie

This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhibitor resistance and why BTK mutation testing matters, and how to sequence therapy now that BTK inhibitors and venetoclax have both moved into the frontline. From there we get into venetoclax retreatment, the pirtobrutinib data from BRUIN CLL-321 and the new BRUIN CLL-322 triplet trial, the real-world CAR T experience that is changing how we think about cell therapy in CLL, bispecific antibodies, and the emerging class of BTK degraders. As always, if you haven't heard the earlier episodes in this series, start there first.If you haven't done so, be sure to check out our original CLL Series and our CLL Updates Part I episode as this update will draw on concepts covered previously!**This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, click here! Be sure to use our SPECIAL TFOC code TFOC40 to save 40% off registration.** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Thirty-three years into her career, UK singer-songwriter Beth Orton continues to captivate critics and audiences with her latest album, The Ground Above. She talks about the new record ahead of her show tomorrow night at Le Poisson Rouge at 6:30 p.m.A new performance space called The People's Theater has recently opened in the Inwood/Washington Heights neighborhood of Upper Manhattan. Mino Lora, the venue's co-founder and executive artistic director talks about the new space and upcoming programming. Plus, artist and activist Manuel Oliver previews his upcoming show 'Guac,' opening Oct. 1, which honors the life of his son who was killed in a school shooting in Parkland, Florida.In the new film "Sunny Dancer," a teenager in remission from leukemia heads to "chemo camp," a summer camp for other teens with cancer. Writer and director George Jaques discusses the film alongside Neil Patrick Harris, who stars as the director of the camp. "Sunny Dancer" premieres on September 18.Photo: Neil Patrick Harris in 'Sunny Dancer.' (photo by Colin J Smith) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Mariateresa Fulciniti and Angelo D'Alessandro on their latest articles published in Blood. Dr. Fulciniti, of the Dana Farber Cancer Institute, discusses the development of "PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma" starting from the question, "Is 17P loss simply a prognostic marker, or does it create specific vulnerabilities that we can therapeutically exploit?" Then, Dr. D'Alessandro, of the University of Colorado, discusses "The red blood cell proteome and interactome identify a Band 3–BLVRB axis regulating hypoxic metabolic adaptation." His team began by asking, "What's in a red blood cell? How many proteins are there, and how can we confidently claim that these now several 1000s of proteins in opposite excess are indeed proteins within red blood cells are not coming from contaminants?" Both studies describe how deep molecular profiling can uncover specific, potentially targetable biological dependencies or interaction axes that may enable more precise, mechanism‑based therapeutic strategies.

This week we kick off a two-part update to our CLL series, covering what has changed in frontline management since our original episodes. Using the case of a 68-year-old man with newly diagnosed, symptomatic CLL, we revisit the essential steps before treatment: confirming an indication to treat, ruling out Richter's transformation, and risk stratification, with the history behind FISH cytogenetics, IGHV status, and the CLL-IPI. We then trace how continuous BTK inhibitors and fixed-duration venetoclax-obinutuzumab displaced chemoimmunotherapy, before digging into the trials reshaping practice in 2026: AMPLIFY, SEQUOIA Arm D, and CLL17. Along the way, we cover the open questions for TP53-aberrant disease and why MRD, although prognostic, is not yet a reliable guide for treatment decisions with novel agents. If you haven't done so, be sure to check out our original CLL Series, as these updates will draw on concepts covered previously!**This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, click here! Be sure to use our SPECIAL TFOC code TFOC40 to save 40% off registration.** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Send us Fan MailEvening Prayer (Steadfast Love; Cleansing; Christian Leaders / families; Serious Illness / Leukemia; Children Losing Parents; Thanks to God)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Download the transcript here

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Listen to the podcast here

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Thomas Milne and Dominique Bonnet on their latest articles published in volume 147 issue 24 of Blood. Dr. Milne discusses how transcription factors simultaneously activate enhancers and connect them to their target genes in KMT2A-rearranged acute lymphoblastic leukemia. The binding of MYB, a key hematopoietic TF, is sufficient to drive novel enhancer activation, including initiating 3D contact with target promoters to drive ectopic expression of distal oncogenes.  Continued MYB binding is required to maintain enhancer-promoter interactions, indicating that disruption of MYB is therapeutically tractable in multiple leukemias. Then, considering bone marrow vasculature, Dr. Bonnet discusses how the use of in vivo models to identify selective injury to sinusoidal endothelial cells caused by venetoclax-azacitidine, revealed a therapy-associated mechanism that links BM niche damage to impaired hematopoietic recovery. These data help explain the prolonged BM hypoplasia observed in some patients and prompt further research into how other targeted therapy-based induction regimens influence the BM microenvironment.Featured ArticlesMYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemiaRemodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage

PVEK and the Changing Treatment Landscape for BPDCN On this episode host Dr. Ryan Haumschild, Vice President of Pharmacy at Emory, is joined by Dr. Naveen Pemmaraju, Professor of Leukemia and founding director of the BPDCN program at MD Anderson, to discuss blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer. They examine the recent FDA approval of pivekimab sunirine-pvzy (PVEK), a CD123-directed antibody-drug conjugate, and results from the CADENZA trial in both treatment-naive and relapsed or refractory patients. The conversation explores where PVEK may fit within the evolving BPDCN treatment landscape, its safety and outpatient administration, and the role of targeted therapies in helping eligible patients reach stem cell transplant. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Send us Fan MailEvening Prayer (Strengthen Marriage and Families; Leukemia; Rest for weary) #Jesus #Eveningprayer #Christian Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

In this months Cancer Prevention segment, Matt Brooks and Courtney Maxson, Senior Public Health Educator from the Cortland County Health Department discuss different types of cancers and how to prevent[Read More...] The post September is the Awareness Month for Leukemia, Lymphoma, Ovarian, Prostate, Thyroid, Gynecologic, and Childhood Cancer appeared first on X101 Always Classic - WXHC.com.

PJ hears from country singer Mags McCarthy whose dad was cured of Leukemia from transplants in Dublin's St James Hospital and from Dr Bruce Levine, a pioneer in the field of cell and gene therapy and Dr. Vitaliy Mykytiv, Consultant Hematologist and Clinical Director of Diagnosis and Therapeutics at Cork University Hospital Hosted on Acast. See acast.com/privacy for more information.

In this week's episode, Blood editor Laurie Sehn interviews Drs. Efstathios Kastritis and Lucia Chen on their latest articles published in Blood. Dr. Kastritis shares insights and results from the final survival analysis of the ANDROMEDA trial, which determined that adding daratumumab to cyclophosphamide, bortezomib, and dexamethasone improves hematologic responses and overall survival in newly diagnosed AL amyloidosis.  Dr. Chen elaborates on the key benefits of Ikaros degradation for reducing T-cell dysfunction in MM patients: Ikaros degradation by mezigdomide enhances anti–B-cell maturation antigen CAR-T and bispecific TCE therapy efficacy in vitro and in vivo. Featured Articles: Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone for Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis | Efstathios KastritisIkaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies | Lucia Chen

Peter McLaughlin was given a twin diagnosis 23 years ago: Lyme disease and leukemia on the same day. The doctors told him if he was lucky, he had 10 years. They didn't know what caused it and they didn't know how to cure it. So he went looking himself. What he found in the depths of his own psyche became the foundation of an entire life's work in hypnotherapy, past life regression, Havening, and subconscious reprogramming. He's been healthy for 23 years. And in this conversation, he shares what he learned along the way, including one of the most fascinating explanations I've ever heard for why we drink. We get into what hypnosis actually is and why the entertainment version of it has given most people completely the wrong idea. We talk about how trauma gets encoded in the nervous system as safe or not safe, and why that single distinction explains almost every self-sabotaging pattern people can't seem to break. We go into past life regression, what happens emotionally when someone encounters a lifetime they consciously have no memory of.  And we talk about alcohol. Specifically, why it's called spirits. What it actually does energetically when you drink. And how Peter uses future progression in hypnosis to help people feel, in their body, the 10-year contrast between two versions of their life, one that keeps drinking and one that doesn't.   IN THIS EPISODE  The twin diagnosis that sent Peter into the depths of his own subconscious, and what he found there What hypnosis actually is, why the entertainment version gets it completely wrong, and the everyday experience almost everyone has had that is genuinely hypnotic Why alcohol is called spirits, and what Peter believes is actually happening energetically when you drink How root cause healing differs from symptom management, and why going back to the origin of a pattern is the only thing that actually resolves it Past life regression: what it feels like from the inside, what happens emotionally, and why the most mundane past lives are often the most moving Havening: what it is, how it works, and why the magic isn't in the tapping The future progression technique Peter uses with clients, and why the 10-year contrast is so powerful Why other people don't give you love, they just trigger the feelings you're already capable of generating yourself The one book Peter recommends above all others, and why he reread it after his father died   Find Peter at blueskyhypnosis.com and on YouTube at Blue Sky Hypnosis, where his past life regression track has nearly a million views. Join over 20,000 souls who tune into weekly newsletters on the competitive advantage you get alcohol-free. Get on the Euphoric newsletter. Apply to be our next Thought Leader to master premium selling and thought leader positioning to publish your book and deliver your keynote onstage.  Euphoric the Club is the premier space to lose the desire for alcohol as you surround yourself with successful women who don't drink (and the women who are becoming them). Euphoric the Club includes full access to all of my alcohol-free programs to make alcohol meaningless as your dreams take center stage, meaningful monthly challenges, weekly coaching and more.  If you know you're meant to help other people change their relationship with alcohol and create a profitable online brand, be sure to get on the waitlist for the Empowered AF Coach 5x Certification – and get 5x certified as a world class alcohol-free empowerment coach, subconscious change coach, success coach, NLP practitioner, and hypnosis practitioner and implement our 0 to $100k Coach Method™ as your build a profitable brand.  Profiling successful people who don't drink and where the alcohol-free lifestyle and entrepreneurship collide. Subscribe to the Euphoric AF YouTube channel. Read Euphoric: my HarperCollins bestseller on losing the desire for alcohol while getting high on your dream life. Be sure to get your copy of Euphoric: Ditch Alcohol and Gain a Happier, More Confident You today or grab your free chapter here.  Follow @euphoric.af on Instagram.  Please do rate, review, and subscribe so we can continue spreading our message far and wide!

Today on the PDX Pet Connection podcast, I have Kelly Shannon of At by Kelly Shannon. Stay tuned to hear how she got started on her art journey, which led her to create custom pet portraits and whimsical art pieces featuring adorable critters. She also shares her inspiring story of how her art helped her through her battle with Leukemia. You can find more information about Art By Kelly Shannon on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠her website and by following her on ⁠⁠Facebook⁠ and ⁠Instagram⁠⁠⁠⁠. I hope you enjoy this episode with your furry best friend.Learn more about PUGapalooza on their event website. For the Bridgetown Veterinary Donations (we are spotlighting Kelly's donation), you can learn more on their website.If you enjoyed this podcast and would like to become part of the PDX Pet Connection community, join our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook group⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and connect with other pet parents, businesses, services, and charities.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Joshua Hill and Jeffery Weitz on their latest articles published in Blood. Dr. Hill and Dr. Michaelis discuss the evolving landscape of infection risk in adults receiving bispecific antibody therapies for advanced B‑cell malignancies. They explore how these risks differ from those seen with allogeneic transplant, CAR T‑cell therapy, and traditional CD20‑directed antibodies, and touch on emerging approaches such as trispecific antibodies and evolving strategies for supportive care, including immunoglobulin replacement. In the second half of the episode, Dr. Michaelis is joined by Dr. Jeffrey Weitz to discuss new insights into the role of histidine‑rich glycoprotein in hemostasis. Their conversation delves into HRG's interactions with key platelet receptors, its behavior in inflammatory states like sepsis and COVID‑19, and how these observations may reshape thinking about thrombosis risk and future therapeutic approaches.Featured Articles: How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies | Joshua Hill, MDHistidine-rich glycoprotein modulates platelet adhesion and aggregation by binding to GPIbα and GPIIb/IIIa | Jeffery Weitz, MD

Could one of the most widely used herbicides in America be connected to rising rates of cancer? In this episode, we explore the growing body of research surrounding glyphosate, non-Hodgkin lymphoma, leukemia, and cancer rates across the United States.We take a closer look at Iowa and other agricultural states, where heavy glyphosate use overlaps with elevated rates of certain cancers, and discuss what researchers have found about glyphosate exposure and blood cancers. We also examine CDC biomonitoring data showing how widespread glyphosate exposure is among Americans, including children.You'll learn about the potential mechanisms researchers are investigating, including oxidative stress, DNA damage, immune dysfunction, inflammation, and gut microbiome disruption, and why reducing unnecessary pesticide exposure may be an important part of a long-term approach to health.In this episode:Glyphosate use across the United StatesIowa, agricultural regions, and cancer ratesGlyphosate and non-Hodgkin lymphomaThe research on glyphosate and leukemiaCDC findings on glyphosate exposure in adults and childrenHow glyphosate may contribute to oxidative stress and inflammationPotential effects on the gut microbiome and immune systemPractical ways to reduce everyday pesticide exposureIf you've ever wondered how environmental chemicals may influence cancer risk, immune health, and chronic disease, this episode is for you.Save 15-30% OFF my favourite protein with code 'MARLA': https://www.equipfoods.com/MARLAClearly Filtered water filters (10% off with this link): https://clearlyfiltered.com/WHOLISTICHOMEOPATHBeef organ sticks and beef tallow(code 'MARLA'): https://lineageprovisions.com/MARLAWork with me: https://holisticspring.com/contact

In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.

Some of the most serious diagnoses in pediatrics begin with common pediatric symptoms. A child comes in looking pale or with a febrile illness. They've been more tired than usual. Maybe they're bruising easily or complaining their legs hurt. Individually, none of these symptoms are unusual. Together, or with persistence, they can tell a different story. Leukemia is the most common childhood cancer, but it's earliest signs often resemble everyday illnesses.   The episode introduces Ashley Rogers, MD, a pediatric oncologist at Children's Hospital Colorado and faculty member at the University of Colorado School of Medicine, as the newest host of Charting Pediatrics. As David Brumbaugh concludes his remarkable nine-year tenure as host, he passes the microphone to Dr. Rogers, ushering in the next chapter of the podcast.  Dr. Rogers joins the conversation to share her expertise on childhood leukemia, including key considerations for diagnosis, treatment and the pediatrician's role in recognizing and managing these patients. This episode offers both valuable clinical insights and a warm welcome to a new voice who will continue bringing evidence-based pediatric education to listeners.  Some highlights from this episode include: Earliest signs of leukemia pediatricians can look out for  How to distinguish between viral illnesses or leukemia  Red flags that shouldn't be dismissed  Role of the pediatrician after a leukemia diagnosis   For more information on Children's Colorado, visit: childrenscolorado.org. 

Positive test, negative test, same day, 4 hours apart. WTFFFFFFFFFF IS GOING ONNNNNNNNNNNNNN. AHHHHHHHHHHHH Also 7th Valkyrie news —--------------------- Want more 7th Valkyrie? Check out our Patreon to become a Hero of Edara, where you can shape the future of the series, decide on merch drops and incentives, get early access to new episodes, enjoy bonus features and content, and help us hit the major checkpoints on the Path of Heroes!  https://www.patreon.com/7thvalkyrie  

Send us Fan MailMorning Prayer (Our Eyes Look To The LORD; Forgiveness; Leukemia / Blood disorders; Freedom From Pain; Leaders to Serve Lord; Praise)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Matthew Frank and Jieqing Zhu on their latest articles published in volume 147 issue 22 of Blood. Dr. Frank discusses "How I treat HLH-like toxicities after immune effector cell therapy", in which the two cases presented emphasize the need for early identification, the use of anticytokine therapy with either emapalumab or ruxolitinib when organ toxicities worsen despite conventional CRS-directed treatment, and the need for ancillary supportive care as central to success. Dr. Zhu shares insights from "Structural Basis of HPA-1 a Alloimmunization in FNAIT and Allosteric Regulation of Integrin Conformation" where they probed the structure-function relationships underpinning interactions of alloantibodies against the most common target, human platelet antigen 1a (HPA-1a). Their data can help explain why some alloantibodies cause severe hemorrhagic FNAIT while others result in milder, asymptomatic thrombocytopenia.

What happens when your life changes overnight with a diagnosis that seems impossible to overcome?On this episode of This Week in America with Ric Bratton, author Janet McDowell shares the remarkable true story behind her memoir, Chasing a Light in the Darkness: A Story of Resilience in the Face of Unrelenting Medical Challenges.Shortly after her 61st birthday, Janet was diagnosed with lymphocytic leukemia—a disease often treatable in children but far more difficult for older adults. What followed was a years-long battle that included two near-death experiences, a stem cell transplant, serious rejection complications, and countless setbacks.Yet through every obstacle, Janet refused to surrender hope.In this deeply personal conversation, Janet discusses: Receiving a life-changing leukemia diagnosis Enduring life-threatening medical complications The emotional challenges of asking for help The vital role her sister Susan played as caregiver Finding hope during overwhelming uncertainty Lessons about resilience, courage, gratitude, and perseverance Whether you've faced illness yourself, cared for a loved one, or simply need encouragement during difficult times, Janet's story is a powerful reminder that hope can shine even in life's darkest moments.This Week in America with Ric Bratton is one of America's longest-running and most respected syndicated radio shows and podcasts, heard on more than 100 radio stations and podcast platforms worldwide. Each week, Ric brings listeners compelling conversations with bestselling authors, thought leaders, medical experts, business innovators, and extraordinary individuals whose stories educate, inspire, and entertain.If you're searching for inspiration through cancer recovery, leukemia survivor stories, medical memoirs, stem cell transplant experiences, caregiver support, resilience, hope, and overcoming life's greatest challenges, don't miss this moving conversation with Janet McDowell.https://www.jlmcdowell.comhttps://www.amazon.com/Chasing-Light-Darkness-resilience-unrelenting/dp/B0GFCX6X3Vhttps://mainspringbooks.comKeywordsJanet McDowell, Chasing a Light in the Darkness, leukemia survivor, lymphocytic leukemia, cancer survivor, cancer recovery, stem cell transplant, graft versus host disease, medical memoir, inspirational memoir, resilience, hope, perseverance, caregiver support, family caregiving, overcoming adversity, chronic illness, healing journey, cancer treatment, patient story, health podcast, inspirational author, memoir interview, medical challenges, surviving cancer, This Week in America, Ric Bratton, podcast interview, overcoming illness, hope after cancer

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Days of our Lives spoilers bring a dramatic twist as Joy Wesley (AlexAnn Hopkins) faces a serious health scare, potentially altering the lives of Alex Kiriakis (Robert Scott Wilson) and Stephanie Johnson (Abigail Klein). Jeremy Horton (Trevor Donovan) continues to stir the pot in Salem, resulting in further tension between Joy, Stephanie, and Alex. As the situation unfolds, Stephanie's lack of understanding and empathy for Joy's predicament may exacerbate the situation further.  DOOL spoilers deliver an unexpected turn of events and hint at a devastating diagnosis for Joy, with Leukemia being a possible outcome. This could potentially reveal secrets surrounding the paternity of Kelsey and the alleged tampering of the paternity test. Alternatively, a twist could lead to a plot where Joy loses her battle with cancer, leaving her daughter Kelsey in the joint custody of Alex and Stephanie. This could strain Alex and Stephanie's already fragile marriage to its breaking point.  Spoilers for Days of our Lives anticipate that Belle Black (Martha Madison) attempts to mediate the escalating situation, but is met with resistance from Stephanie. Stephanie's interference in Alex's co-parenting challenges with Joy could further exacerbate the situation. This week, fans are in for a rollercoaster of emotions as Joy's health scare unfolds, potentially revealing hidden secrets and causing a rift in multiple relationships. Soap Dirt is the most subscribed to YouTube soap opera channel. Visit our Days of our Lives section of Soap Dirt: https://soapdirt.com/category/days-of-our-lives/ Listen to our Podcasts: https://soapdirt.podbean.com/ And Check out our always up-to-date Days of our Lives Spoilers page at: https://soapdirt.com/days-of-our-lives-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

Since it came up lately, here is, for the first time to the public, Dave being asked to try a food blindfolded. Also a bonus fact about why scientists can never get that last 0.1% of bacteriaDonate to Rebs' cycling fundraiser here for Leukemia & Lymphoma NI and Laurel House Chemo Unithttps://www.justgiving.com/crowdfunding/rebs-lightbodyNew full episodes every Thursday.Bonus mini-eps on Sundays and Tuesdays.To listen to Dave on the radio check outhttps://www.todayfm.com/shows/dave-moore-1499732 To see Neil on tour check outhttps://www.neildelamere.com/reinventing-the-neil-tourhttps://www.neildelamere.com/neils-on-wheels-tourYou can watch the podcast on Youtubehttps://www.youtube.com/@WhyWouldYouTellMeThatpodcastPresented and Produced by Neil Delamere and Dave MooreEdited by Diarmuid O'BrienMusic by Dave MooreArtwork by Ray McDonnell Hosted on Acast. See acast.com/privacy for more information.

It's Friday. It's Megadeth day. Let's f'ing GOOOOOOOO!!!! Yes, Megadeth & Obituary are at the La Crosse Center tonight and you can still get tickets at the door. Gates open at 5pm and music should start around 7pm. Don't miss Megadeth before they retire from touring FOREVER!!! On this show this morning, we played a bunch of Megadeth tunes to get pumped for the show tonight…and we gazed into the future at some things to look forward to in the month of August. Including movies, TV shows, sporting events, & holidays. Doc joined me just after 8am for this week's racing report thanks to County Materials in Holmen & Eau Claire. In the news this morning, a recall on rechargeable hand warmers, Mandela Barnes drops out of the WI Governor's race, a man gets 15 years in prison for supplying his son the gun used to kill two students & two teachers, the Army has been testing a new weapon with a badass name, In sports, the Brewers are in LA to take on the Angels tonight, more info on the Tony Romo DUI arrest, Deebo Samuel gets a contract extension, Lebron is going to be filming his entire season with the 76ers for an upcoming documentary, and UEFA is going to boycott all FIFA competitions. Let you know what's on TV & streaming this weekend along with what's new in theaters. Plus, Greg Brady joins the Smashing Pumpkins on-stage for a Brady Bunch classic. And a "Clueless" sequel is in the works with Alicia Silverstone on-board. Fantastic story about a postal worker who helped save a baby's life thanks to her years of medical training, and a young Leukemia patient is going viral for her unique decorations while in the hospital. Elsewhere in sports, Paige Bueckers & Angel Reese won't face any discipline from the WNBA over a friend wager made on video, one of the co-owners of the Seattle Storm gets in trouble with the league, the PGA is going to air an announcer-free stream of it's upcoming tournament, and a TOPPS Shohei Ohtani card just sold for a LOT of money. And in today's edition of "Bad News with Happy Music", we had stories about a three year-old kid who snuck out of his house & walked a half mile to grandma's, a naked man hiding in the ceiling of a plasma donation center, a kid who got suspended from school because he bit his sandwich into the shape of a gun, a #FloridaMan who admits it's him on video committing a crime, Aldi was trying to sell four ice cubes for $5, and a woman gets mad about her drive-thru wait at a KFC.See omnystudio.com/listener for privacy information.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy" where the team was able to identify that ultra-low-burden FLT3-ITD microclones are associated with higher relapse risk and inferior relapse-free survival. Their work encourages the evaluation of FLT3 inhibitor strategies. Dr. Basu discusses "CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial". In four patients, the treatment was well tolerated and supported CAR T-cell expansion and persistence, challenging the need for lymphodepletion and supporting chemotherapy-free approaches in autoimmune disease.

In today's episode, we spoke with Jorge E. Cortes, MD, and Elias Jabbour, MD. Dr Cortes is the chief of Hematology in the Division of Hematology and Oncology and the associate director for Translation at the UAB O'Neal Cancer Center in Birmingham, Alabama. Dr Jabbour is a professor of leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.In our exclusive interview, Dr Cortes and Dr Jabbour discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA approval for patients with chronic myeloid leukemia (CML). After diving into the approval itself and the data that supported it, they both discussed why the approval is significant and which patients it will benefit most. In addition to covering the approval, the two also shed light on what is to come for biosimilars and alternate formulations in the greater CML treatment paradigm.

What role does muscle strength play in healthy aging, longevity, and independence? In this episode, Dr. Gillian Lockitch speaks with Jeanne Phares about why maintaining and building muscle becomes increasingly important for women during and after menopause. Drawing on her personal experience as a leukemia survivor and decades of strength training, Jeanne explains the connections between muscle mass, metabolism, bone health, resilience, and recovery. Listeners will learn practical strategies for strength training, nutrition, and lifestyle habits that support vitality and healthspan at every age. Jeanne Phares is Founder of Sage Lifestyle Collective and creator of the Sage Strength Transformation Program. She is a Certified Health & Wellness Coach, Strength Trainer, and author specializing in women's health after 50. Prior to entering the health field, she enjoyed a successful career as a Certified Public Accountant and executive mentor. Her work focuses on strength training, nutrition, menopause education, and healthy aging for women. She helps women build muscle, improve metabolic health, and maintain independence throughout midlife and beyond. A leukemia survivor, she credits decades of strength training with helping her withstand intensive treatment and recovery.  Episode Timeline  00:00 – Welcome and introduction  03:00 – Why muscle strength predicts healthy aging and longevity  04:36 – Jeanne's journey from CPA to health and wellness coach  05:30 – Leukemia diagnosis and the role of physical resilience in recovery  09:30 – Stem cell transplant and rebuilding strength after illness  13:15 – Turning health challenges into opportunities for growth  15:46 – Common misconceptions about lifting weights after 50  18:35 – Why walking and yoga alone may not be enough  20:00 – Muscle health, bone strength, and menopause  23:53 – Strength training as the foundation of healthy aging  25:15 – Nutrition mistakes women commonly make after menopause  28:49 – Hydration, electrolytes, and healthy aging  30:23 – Whole foods nutrition and listening to your body  34:44 – The one simple change that supports lifelong health  36:23 – Final thoughts and key takeaways  Connect with Jeanne Phares Sage Lifestyle Collective  www.sagelifestylepress.com Free Gifts for Listeners: Each guest will receive all three: 1. Free Chapter Download: "Your Body Changed the Rules. Here's the New Playbook" from Eat for Strength for Women Over 50 2.Free Starter Guide: The Sage Strength Starter Guide 3.Lottery Entry: A chance to win one of 10 discount codes for the 8-Week Sage Strength Transformation Program or one of 10 free audiobooks of Eat for Strength for Women Over 50 Books: The Beginner's Guide to Strength Training for Women Over 50 Eat for Strength for Women Over 50  Sage Strength Transformation Program : Free strength training and healthy aging resources  Connect with Your Host: Dr. Gillian Lockitch Email: Askdrgill@gmail.com website: https://askdrgill.com  

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first report from the CHORUS registry for hereditary hemorrhagic telangiectasia (HHT) presented by Dr. Al-Samkari and also the introduction of the ASH Hematomics (ASHOP) platform for integrative genomic data analysis presented by Dr. Zhou. The CHORUS registry reveals that HHT is a progressive, underrecognized inherited bleeding disorder with a substantial burden of recurrent bleeding, iron deficiency, arteriovenous malformations, and life-threatening complications, while emphasizing the need for earlier diagnosis and the development of targeted therapies. The second presentation introduces ASHOP, an open-access platform that enables researchers to explore and integrate large-scale clinical and genomic datasets, facilitating discoveries in leukemia and other hematologic diseases through advanced analytical tools. Together, these studies demonstrate how comprehensive patient registries and innovative data-sharing resources are advancing precision medicine, improving disease understanding, and accelerating future research across hematology.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Haris Sohail and Lucas Kühne on their latest articles published in volume 147 issue 21 of Blood. In this CME article titled, "Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection",  Sohail et al show that IV iron given during acute infection with iron deficiency anemia is associated with improved 14-day and 90-day survival as well as hemoglobin recovery. Although this report has the limitations of a retrospective study, these findings challenge current practice and support randomized trials that include patients with infection. In "Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura", Kühne et al show in a multicenter registry study of 204 patients that refractoriness during caplacizumab treatment in immune TTP is uncommon and, when observed, is typically associated with confounding clinical factors. These findings underscore the importance of careful clinical reassessment and evaluation for alternative etiologies in patients with delayed platelet recovery, rather than attributing such cases to true treatment resistance.

What if the way back to health isn't found in fighting harder… but in reconnecting with nature? After being diagnosed with leukemia and lymphoma, Dean Hall made a decision that left even his doctors shaking their heads. He swam 187 miles of Oregon's longest river. He embraced a practice known as forest bathing. Today, Dean is in remission! Coincidence? Conviction? Or is there more to this story? In this week's episode, Autumn and Dean explore a radically different conversation about healing, purpose, grief, the nervous system, and our relationship with the natural world God created. This conversation may completely change the way you think about striving for health, supporting the body's ability to heal, and God's fingerprints woven throughout creation.

At just 16 years old, Hayden Laufgraven heard the words no teenager expects:"You have leukemia."What followed was hospitalisation, chemotherapy, a bone marrow transplant, remission, relapse, another transplant, months of isolation, and learning how to never give up. In this deeply moving episode of Talking Smack 415, Jamie the Great and I sit down with Hayden to talk about what it's really like to be diagnosed with Acute Myeloid Leukemia (AML) as a teenager, the emotional toll of the diagnosis and surviving cancer, and the often-overlooked reality of PTSD after cancer treatment.Hayden shares his remarkable perspective on resilience, friendship, identity, and why surviving cancer doesn't mean the journey is over.Whether you've experienced cancer yourself, love someone who has, or simply need a reminder of the strength of the human spirit, this conversation will stay with you long after it ends. Hayden is wise beyond his years. In this episode we discuss:What it's like being diagnosed with Acute Myeloid Leukemia (AML) at age 16The signs and symptoms that led to his leukemia diagnosisChemotherapy, remission, relapse, and undergoing two bone marrow transplantsHow donor registries and bone marrow matching workThe physical and emotional impact of cancer treatmentPTSD and trauma after surviving cancerRebuilding strength after months of chemotherapy and isolationThe importance of friendship, family, and community during illnessMental resilience and finding hope through uncertaintyLife after cancer and returning to college, sports, and everyday lifeHayden's honesty, maturity, and optimism offer an extraordinary reminder that resilience isn't about pretending you're fearless—it's about continuing to move forward anyway.Follow Hayden on TikTok: @haydenlaufIf this episode resonates with you...Please subscribe, rate, and review Talking Smack 415. Sharing this episode may help someone navigating cancer, supporting a loved one through treatment, or healing from the invisible emotional scars that often remain after remission.Cancer changes lives—but so does hope.Share this episode with your friends and family who love to laugh.  Subscribe to Talking Smack 415 and leave us a rating and review so more peeps can find us for laughter and friendship to feed your soul!  

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the latest highlights from the EHA 2026 conference, focusing on groundbreaking studies in the leukemia space. Join us as we welcome Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center to discuss three pivotal studies: OPTI-AML: explored the findings on the use of venetoclax in combination with azacitidine for newly diagnosed AML patients, comparing 14-day versus 28-day treatment regimens and their impact on cytopenias and overall outcomes. KOMET-007: promising early data on menin inhibitors, specifically Ziftomenib, in frontline settings for patients with NPM1 and KMT2A rearrangements, and how it may change the landscape of AML treatment. SENTRY: analyzed the combination of ruxolitinib and selinexor for myelofibrosis, discussing its effects on spleen volume reduction and overall survival, as well as the implications of side effects. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/  Tune in for an insightful discussion on the future of leukemia treatment and the importance of genetic markers in therapy decisions. Don't forget to like, subscribe, and check out our other conference highlights from ASCO and EHA! #EHA2026, #Leukemia, #AML, #Myelofibrosis, #OncologyBrothers  

MY PLUMPUS IS SAFE!!!!!! THE VET USED A TEST THAT WAS STUPID AND DUMB AND GAVE FALSE POSITIVES! And that was the last of my energy I'm dying of exhaustion, but I love y'all —--------------------- Want more 7th Valkyrie? Check out our Patreon to become a Hero of Edara, where you can shape the future of the series, decide on merch drops and incentives, get early access to new episodes, enjoy bonus features and content, and help us hit the major checkpoints on the Path of Heroes!  https://www.patreon.com/7thvalkyrie  

It's Thursday, July 9. Here are today's top stories around Central Indiana. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org and follow us on social media to get local news every day. WFYI News Now is hosted by Barb Anguiano and produced by Zach Bundy. Subscribe wherever you get your podcasts.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Kirsty Hillier and Marco Ruella on their latest articles published in Blood. For "Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model", Dr. Hillier shares the potential benefits of incorporating this new model to enhance the care of the 1 in 4 patients who develop chronic ITP. As an alternative to current guidelines which advise providers to "wait and see", this online model determines patients who are at risk for chronic ITP, allowing for providers to make informed decisions on their continued care. In "Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies", Dr. Ruella explains how the treatment of T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective antitumor responses while preventing CAR T-cell fratricide. The team found that CD2 was a viable target, especially combined with a novel PD-1:CD2 switch receptor to remedy dysfunction caused by CD2 deletion.  

Which is like a weird space to be in for "might". Ya know? This is one of the weirdest TABTAs of all time. Got some good stuff coming your way though. —--------------------- Want more 7th Valkyrie? Check out our Patreon to become a Hero of Edara, where you can shape the future of the series, decide on merch drops and incentives, get early access to new episodes, enjoy bonus features and content, and help us hit the major checkpoints on the Path of Heroes!  https://www.patreon.com/7thvalkyrie  

In today's episode, we spoke with Courtney D. DiNardo, MD, MSCE, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and an associate member of The University of Texas Graduate School of Biomedical Sciences in Houston.In our exclusive interview, Dr DiNardo discussed the May 2026 FDA approval of decitabine (Dacogen) and cedazuridine (Inqovi) plus venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia (AML). DiNardo outlined numerous important facets of the approval, including its effects on the treatment paradigm, which patients will benefit most, safety considerations with the regimen, and quality of life advantages that have been observed with the combination. Furthermore, she discussed how this approval fits into a larger shift for the AML treatment paradigm and how the AML research field can build upon the approval of this regimen.

Jeff Granville, Founder and President of Mindful Presents is a Mindfulness Practitioner. Coherence Counselor. Spiritual Advisor, and Trauma Specialist. He is endorsed by Bruce H. Lipton, Ph.D., and Bruce Cryer, former CEO, HeartMath. Jeff served for 4 years as a member of the Family advisory council at Seattle Children's Hospital and trained as a first responder in the Parent Support team. He served on the nurse training, anesthesiologist training, Root Cause Analysis and Hospital Acquired Condition panels. As well as consultant to the clinical efficacy department.Jeff is a 5th generation inhabitant of the San Juan Islands, growing up on and around the waters or the Pacific Northwest. And is a father of 8 and Grandfather of 10 beautiful children.After his youngest son Makoy was diagnosed with a rare form of T-cell Leukemia, Jeff became a Mindfulness Practitioner and formed the nonprofit Mindful Presents to bring the gift of mindfulness, coherence and controlled breathing to pediatric patients, families and care providers.Since then, Jeff has opened up his services to the general public and specializes in Coherence Breathing, STIR; Somatic Trauma Imprint Release and aspect reintegration.Mindfulpresents.orgjeff@mindfulpresents.orghttps://www.facebook.com/MindfulPresents.orghttps://www.youtube.com/@jeffgranville4790360-941-7005More about Liz:Work- https://www.raisethevibewithliz.com/Radio Show- https://www.voiceofvashon.org/raise-the-vibePodcast- https://www.buzzsprout.com/958816Facebook- https://www.facebook.com/raisethevibewithlizInstagram- https://www.instagram.com/raisethevibewithliz/*** Support the show! https://www.buzzsprout.com/958816/supporthttps://paypal.me/LisbethPeterson?country.x=US&locale.x=en_USJoin The Community!

Adriana Luna and her fiancé, Anthony Lerma, weren’t expecting any babies at all when they discovered they were going to have four. AND The Massachusetts teen completed a marathon at a hospital despite battling leukemia, and the whole medical facility had his back. To see videos and photos referenced in this episode, visit GodUpdates! https://www.godtube.com/blog/birth-to-quadruplets.html https://www.godtube.com/blog/teen-completes-marathon-at-hospital.html Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

What if the reason you feel stuck has nothing to do with willpower? Hypnotherapist Peter McLaughlin breaks down the truth about the subconscious mind and how it impacts your habits, relationships, and healing. After being diagnosed with Leukemia and Lyme disease, he was told he had 10 years to live. So Peter began exploring the mind-body connection, and what he discovered not only changed his life, but became his life’s work.